Ghana becomes first river blindness-endemic country to approve moxidectin

‍Medicines Development for Global Health (MDGH) announced today that the Ghana Food and Drugs Authority (FDA) has approved the marketing authorisation application for moxidectin 2 mg oral tablets for the treatment of river blindness (onchocerciasis) in adults and children aged 4 years and older.